Disturbance of the 5-hydroxytryptamine metabolism in brains from patients with Alzheimer's dementia
- PMID: 2202785
- DOI: 10.1007/978-3-7091-3345-3_4
Disturbance of the 5-hydroxytryptamine metabolism in brains from patients with Alzheimer's dementia
Abstract
The 5-hydroxytryptamine (5-HT) system in the human brain is sensitive to aging. In dementia of the Alzheimer type (AD/SDAT), there are significantly reduced concentrations of 5-HT and 5-hydroxyindoleacetic acid (5-HIAA). 5-HT-sensitive imipramine binding is reduced by almost 50%, indicating a loss of presynaptic 5-HT terminals. There also seems to be reduced tryptophan hydroxylase activity in some brain areas. In cerebrospinal fluid (CSF) from AD/SDAT patients, the concentration of 5-HIAA is reduced, and the accumulation of 5-HIAA after probenecid loading is diminished. Biochemical findings together with structural findings in the raphe nuclei indicate that the disturbance of the 5-HT system is of the same magnitude as the disturbance of the cholinergic system. Reduced activity in the 5-HT system may be of importance for activity in the hypothalamus. There is an increased concentration of arginine vasopressin, which may explain the increased activity in the hypothalamic-pituitary-adrenal axis seen in patients with AD/SDAT. This activity is reduced when a selective 5-HT reuptake blocker is given. Pharmacological treatment with 5-HT reuptake blockers improves emotional disturbances, confusion, anxiety and depressed mood in patients with AD/SDAT.
Similar articles
-
A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease.J Neurol Sci. 1988 Mar;84(1):101-16. doi: 10.1016/0022-510x(88)90179-7. J Neurol Sci. 1988. PMID: 2452858
-
5-Hydroxytryptamine-sensitive [3H]imipramine binding of protein nature in the human brain. II. Effect of normal aging and dementia disorders.Brain Res. 1987 Nov 3;425(1):137-45. doi: 10.1016/0006-8993(87)90492-6. Brain Res. 1987. PMID: 3427415
-
Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia.Neurosci Lett. 1992 Jul 6;141(1):9-12. doi: 10.1016/0304-3940(92)90322-x. Neurosci Lett. 1992. PMID: 1508406
-
Ascending monoaminergic systems alterations in Alzheimer's disease. translating basic science into clinical care.Neurosci Biobehav Rev. 2013 Sep;37(8):1363-79. doi: 10.1016/j.neubiorev.2013.05.008. Epub 2013 May 24. Neurosci Biobehav Rev. 2013. PMID: 23707776 Review.
-
Neurochemical aspects on aging and diseases with cognitive impairment.J Neurosci Res. 1990 Dec;27(4):541-7. doi: 10.1002/jnr.490270415. J Neurosci Res. 1990. PMID: 2079715 Review.
Cited by
-
Serotonergic system, cognition, and BPSD in Alzheimer's disease.Neurosci Lett. 2019 Jun 21;704:36-44. doi: 10.1016/j.neulet.2019.03.050. Epub 2019 Apr 1. Neurosci Lett. 2019. PMID: 30946928 Free PMC article. Review.
-
Deciphering the Functions of Raphe-Hippocampal Serotonergic and Glutamatergic Circuits and Their Deficits in Alzheimer's Disease.Int J Mol Sci. 2025 Jan 30;26(3):1234. doi: 10.3390/ijms26031234. Int J Mol Sci. 2025. PMID: 39941002 Free PMC article. Review.
-
Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice.Exp Neurol. 2007 May;205(1):166-76. doi: 10.1016/j.expneurol.2007.01.037. Epub 2007 Feb 13. Exp Neurol. 2007. PMID: 17368447 Free PMC article.
-
Neural circuits expressing the serotonin 2C receptor regulate memory in mice and humans.Sci Adv. 2024 Jun 28;10(26):eadl2675. doi: 10.1126/sciadv.adl2675. Epub 2024 Jun 28. Sci Adv. 2024. PMID: 38941473 Free PMC article.
-
CHF2819: pharmacological profile of a novel acetylcholinesterase inhibitor.CNS Drug Rev. 2002 Spring;8(1):53-69. doi: 10.1111/j.1527-3458.2002.tb00215.x. CNS Drug Rev. 2002. PMID: 12070526 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical